Literature DB >> 22960647

Infectious keratitis after Boston type 1 keratoprosthesis implantation.

Clara C Chan1, Edward J Holland.   

Abstract

PURPOSE: To determine the incidence, clinical features, and outcomes of infectious keratitis after Boston type 1 keratoprosthesis (Kpro) implantation.
METHODS: Ten cases of infectious keratitis were identified in a retrospective chart review of 105 patients (126 eyes) who received Kpro between November 2004 and November 2010 at the Cincinnati Eye Institute and were followed for at least 1 month (range, 1-66 months; mean, 25 months).
RESULTS: The incidence was 7.9%. Patient diagnoses included 4 chemical injuries, 3 Stevens-Johnson syndrome, 2 ocular cicatricial pemphigoid, and 1 congenital aniridia. Kpro implantation was indicated in 2 eyes for a failed ocular surface and in 8 for penetrating keratoplasty failure. Four patients were contact lens intolerant or noncompliant. All were on topical vancomycin and moxifloxacin for prophylaxis and 2 were on topical amphotericin for prophylaxis. Three infiltrates were culture negative, 5 were fungal (3 Candida, 1 Fusarium, 1 Dactylaria constricta), and 2 were bacterial (Rhodococcus equi and Gram-negative cocci). All patients were managed with topical agents and 4 were given an oral antifungal agent. Four patients had Kpro removal with therapeutic penetrating keratoplasty and 1 had Kpro replacement. At final follow-up, only 2 patients retained their preinfection best vision. Risk factors for infectious keratitis included a diagnosis of cicatrizing conjunctivitis (Stevens-Johnson syndrome, ocular cicatricial pemphigoid, or chemical injury) and a history of persistent epithelial defect (P = 0.0003 and 0.0142, respectively). Contact lens wear, vancomycin use, and a history of systemic immunosuppression (or use at the time of infection) were not statistically significant risk factors.
CONCLUSIONS: Infectious keratitis after Kpro can occur even when patients are on vancomycin and a fourth-generation fluoroquinolone for prophylaxis. Fungal organisms are a growing cause for concern, and we present the details of the first reported case of ocular D. constricta. The evolution of our management and prophylaxis strategy for fungal keratitis after Kpro implantation is also described.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960647     DOI: 10.1097/ICO.0b013e318245c02a

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  15 in total

1.  Effectiveness of antimicrobial peptide immobilization for preventing perioperative cornea implant-associated bacterial infection.

Authors:  Xiao Wei Tan; Tze Wei Goh; P Saraswathi; Chan Lwin Nyein; Melina Setiawan; Andri Riau; R Lakshminarayanan; Shouping Liu; Donald Tan; Roger W Beuerman; Jodhbir S Mehta
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 2.  Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid.

Authors:  Silvia Odorcic; Wolfgang Haas; Michael S Gilmore; Claes H Dohlman
Journal:  Cornea       Date:  2015-12       Impact factor: 2.651

3.  Boston keratoprosthesis type 1: outcomes of the first 38 cases performed at Moorfields Eye Hospital.

Authors:  Chameen Samarawickrama; Nicholas Strouthidis; Mark R Wilkins
Journal:  Eye (Lond)       Date:  2018-02-14       Impact factor: 3.775

Review 4.  Endophthalmitis in Boston keratoprosthesis: case series and review of literature.

Authors:  Jay Chhablani; Bhavik Panchal; Taraparasad Das; Avinash Pathegay; Swapna R Motukupally; Rajeev Reddy Pappuru; Sayan Basu; Virender Sangwan
Journal:  Int Ophthalmol       Date:  2014-09-03       Impact factor: 2.031

5.  Anatomical survival and visual prognosis of Boston type I keratoprosthesis in challenging cases.

Authors:  Maria Fideliz de la Paz; Josef Stoiber; Valeria de Rezende Couto Nascimento; Juan Alvarez de Toledo; Orang Seyeddain; Wolfgang Hitzl; Günther Grabner; Rafael I Barraquer; Ralph Michael
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-25       Impact factor: 3.117

6.  Erratum to: Endophthalmitis in Boston keratoprosthesis: case series and review of literature.

Authors:  Jay Chhablani; Bhavik Panchal; Taraparasad Das; Avinash Pathengay; Swapna R Motukupally; Rajeev Reddy Pappuru; Sayan Basu; Virender Sangwan
Journal:  Int Ophthalmol       Date:  2015-02       Impact factor: 2.031

7.  Current Concepts in the Management of Unique Post-keratoplasty Infections.

Authors:  Julie M Schallhorn; Jennifer Rose-Nussbaumer
Journal:  Curr Ophthalmol Rep       Date:  2015-06-12

8.  Corneal graft dellen in a patient implanted with a Boston keratoprosthesis type 1.

Authors:  Riccardo Scotto; Aldo Vagge; Carlo E Traverso
Journal:  Int Ophthalmol       Date:  2016-04-11       Impact factor: 2.031

9.  Prophylactic Vancomycin Drops Reduce the Severity of Early Bacterial Keratitis in Keratoprosthesis.

Authors:  Aris Konstantopoulos; Xiao Wei Tan; Gwendoline Tze Wei Goh; Padmanabhan Saraswathi; Liyan Chen; Chan Lwin Nyein; Lei Zhou; Roger Beuerman; Donald Tiang Hwee Tan; Jod S Mehta; Jod Mehta
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

Review 10.  Boston keratoprosthesis - Clinical outcomes with wider geographic use and expanding indications - A systematic review.

Authors:  Khalid Al Arfaj
Journal:  Saudi J Ophthalmol       Date:  2015-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.